Medicareer has named the California Biotech Law Blog to be on its list of Top 50 Biotech Blogs.

The California Biotech Law Blog joins  a number of well-regarded publications, which also made the list such as the  In Vivo Blog and the  BioHealth Investor.  The list also includes a number of blogs that I have not previously come across, which we at the California Biotech Law Blog look forward to checking out.

The California Biotech Law Blog thanks  Emily Johnston of Medicareer for letting us know that we were included on this list!  It is an honor to be recognized among so many other biotech publications on the Internet.

I was recently interviewed by Clara Cottrell of TheScitechLawyer regarding the challenges of building a law firm and my advice for lawyers who are trying to build firms or even just simply build careers in these difficult economic times.

To read the article in full, please click here:

http://prinzlawoffice.com/wp-content/uploads/2010/01/scitechprofilekristieprinz1.pdf.

I recently sat down with IP Society’s Patrick Reilly to discuss intellectual property licensing and what start-ups seeking legal counsel need to know about intellectual property licensing.  The focus of the interview was on technology licensing, particularly in the software area, rather than biotechnology licensing, but I wanted to bring it to the attention of blog readers, since the interview may be of interest to many of you.

Click here to view the video.

Technology Transfer Tactics recently interviewed me on the issue of whether poster presentations jeopardize a tech transfer office’s commercialization efforts.

I wanted to share the interview because the article raised some interesting questions.  Of course, universities have long been dealing with the challenges of having to reconcile the competing interests of the educational/research institution’s desire to publish and provide educational opportunities to students vs. the intellectual property protection/commercialization goals of a tech transfer office.  However, this article addressed a unique aspect of that conflict, which I think will be of interest to blog readers.

Following up on our recent coverage of the patent reform debate, Genetic Engineering & Biotechnology News recently interviewed me for their article Patent Reform Battle Pits Biotech against High-Tech. The interview addressed the competing perspectives of the biotech and high tech industries on the issue of patent reform.

Dow Jones Marketwatch Reporter John Letzing recently interviewed me regarding patent holding companies and the subject of patent reform generally.  While the interviews focus more on the high tech industry than the biotech industry, I think that my blog readers will want to read the articles, as  John did an excellent job in addressing the issues.

Speculator of Mundane Patents Casts a Long Shadow

Lawmakers Take Aim at Patent Speculators

As many of you are likely aware, I have had a number of recent interviews and speaking engagements.  The most recent interview was with Sky Radio’s Dennis Michaels.

I sat down with Dennis to discuss some of the recent developments facing the biotech industry, including the MedImmune v. Genentech decision, the generics legislation introduced earlier this year (this was taped prior to the introduction of the new legislation), and the increase in biotech outsourcing.  Dennis provided me a copy of the audio recording of the interview, which I wanted to share with blog readers.  Please click here to listen.

I recently sat down with LexBlog’s Rob La Gatta, who interviewed me in conjunction with LexBlog’s "Five Questions Series."  In the interview, Rob explored how I stay on top of developments in the blogosphere, how I’ve set myself apart to reporters who use me as a source, how I’ve set myself apart from other bloggers, what I see happening with regulation in the blogosphere, and whether I’ve accomplished what I aspired to yet with my blog. 

Since I try to stay on topic with this blog and don’t often talk about myself, this interview provides some insight into me, my firm, and my views on blogging generally that likely goes beyond what you will read in my blog yourself.  

LexBlog has, of course, written about me in the past–Kevin O’Keefe was kind enough to compliment me in a prior blog posting "Be an A-List Blogger in Your Niche to Succeed," where he pointed to me as an example of how you can become successful by blogging in a niche such as biotechnology. 

To follow up on this recent LexBlog interview, as well as Kevin’s earlier posting, I think that that in many ways the web is the great equalizer for legal practices–it enables the small firm practice to distinguish itself in ways that small firms previously could not.  By providing quality content on a relevant subject, lawyers can absolutely become known as experts in a field, even without doing it from the corner office of a swanky large-firm office building.  I have been building my firm for a little over three years now, which was a challenge I took on unexpectedly only after the sudden collapse of my former firm, Pennie & Edmonds LLP.  While, at the time of the collapse, when I decided to start the firm, I had a sixth sense that I should put my resources into developing my web presence and I had a definite vision about how to accomplish this, even I would not have expected to be getting the caliber of media calls and speaking engagements that I am now getting three years later.   

So, thank you to Rob La Gatta and LexBlog for interviewing me, and I hope you, as my blog readers, enjoy this brief glimpse into the story behind the blog. 

I had the opportunity last night to represent the California Biotech Law Blog at the Bay Area Blawgers Event, where I met many of the Bay Area’s most prominent blawgers.  Law Professor Eric Goldman at Santa Clara University organized the event, which was attended by more than forty-five blawgers and members of the media, including yours truly. 

It was a great privilege to be in the presence of so many Bay Area blawgers, and to have the opportunity to hear first-hand their thoughts on why they blog, how they dealt with the challenges they have encountered in blogging, and the role we are all playing in developing the law today.

The event was such a success that there are already plans in the works for a second Bay Area Blawgers Event later this year. 

While the focus of the California Biotech Law Blog has always been very targeted on the subject of California biotech law, this event gave me occasion to step back and look at this blog as part of a larger community of blawgs.  We have some very impressive company.

What thoughts did I take away from this event, which are relevant to you as readers of this Blog?

First, I was struck by the fact that the audience of this Blog is very different from the audience of many of my blawger colleagues.  The scope of this Blog crosses over a variety of professions and skillsets, all of which share an interest in the very specialized area of biotech law.  This was in sharp contrast with the audience of many of my colleagues’ blawgs.

Second, due to the nature of this Blog, we have not run into some of the challenges that many of my colleagues have encountered.  This is in large part because we’ve not yet created the same level of controversy with this Blog. is this good or bad?  I am not sure–perhaps it is the nature of our subject matter.  Or our audience.  Certainly, we in the industry have our opinions on the issues, but it may be that we just do not voice them as strongly in this Blog setting as others do. Perhaps this will change down the road.

Third, the tone this Blog has taken to date has been more educational in nature than pushing a particular perspective or agenda.  This was in contrast to some of the other blawgs represented at the event. 

My final thoughts on this issue: this Blog is still a young blawg and I know that this event and the greater awareness of the larger blawgging community will impact in some way its development.  I thank everyone who participated yesterday for giving me the opportunity to develop a better understanding or this Blog’s role in the greater Bay Area blawg community.  I am confident that this will work to the benefit of the California Biotech Law Blog, both in its short-term and long-term development.